New vaccine combo targets hard-to-treat cancers
NCT ID NCT04117087
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 18 times
Summary
This early-phase study tests a vaccine targeting mutant KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in patients with colorectal or pancreatic cancer that has been surgically removed. The goal is to see if the combination is safe and boosts the immune system's ability to fight these cancers. The study involves 27 participants and focuses on safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.